GXD-Bio and Abion File Global Patent Infringement Lawsuit

GXD-Bio, a bio patent-specialized subsidiary of Intellectual Discovery (co-CEOs Yoon Sangchul and Kim Seoin), Korea's first patent management company (NPE), announced on the 23rd that it is drawing attention after filing a European patent infringement lawsuit against a global breast cancer diagnostics company in collaboration with Abion (CEO Shin Youngki).

This lawsuit was filed with the Unified Patent Court (UPC) in Europe, alleging that global leaders in cancer diagnostics, Myriad Genetics and Eurobio Scientific, infringed on a core patent through their gene expression-based breast cancer prognosis diagnostic product, 'Endopredict.' The patent in question is a technology developed over approximately 12 years by the research team of Professor Shin Youngki of Seoul National University. After being jointly held with Genecurix, a leading Korean cancer diagnostics company, the rights were transferred to GXD-Bio.

GXD-Bio is a subsidiary of Intellectual Discovery specializing in bio patent licensing and commercialization. Within the Intellectual Discovery Group, where Experix is the largest shareholder, GXD-Bio oversees the acquisition, enforcement, and technology transfer of bio and healthcare IP. Through this lawsuit, GXD-Bio is strengthening the protection of this patent's rights in the European market and accelerating efforts to enhance the value of global bio IP.

This UPC lawsuit is expected to set a meaningful precedent for securing substantial intellectual property protection for Korean bio technology in the global market, including Europe. The hearing is scheduled for November.

Bae Dongseok, CEO of GXD-Bio, stated, "This lawsuit marks a critical turning point in confirming the potential for international IP protection of Korean bio technology," adding, "We will continue to strengthen monetization and protection strategies for core patents in the global market through collaboration with domestic bio companies."

Meanwhile, Shin Youngki, CEO of Abion, is a former professor at the College of Pharmacy, Seoul National University, and is pioneering a new era in drug development by integrating AI and bio technology. His laboratory is conducting candidate substance discovery and analysis using AI algorithms and, together with Experix, FuriosaAI, and Intellectual Discovery, has formed 'Team Korea' to actively pursue global IP strategies, including entry into the Middle Eastern market.

Intellectual Discovery plans to further strengthen its acquisition and monetization models for technology-intensive core bio IP in connection with its strategic investment directions in AI semiconductors and AI bio ventures.